Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University, is receiving the award, which is presented to individuals who demonstrate excellence in pharmacy practice leadership.
Over the decades, the American Society of Health-System Pharmacists (ASHP) has been there during the career of Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST.
At this year’s ASHP Midyear Clinical Meeting & Exposition, Chisholm-Burns, executive vice president and provost at Oregon Health and Science University, will be receiving the ASHP Board of Directors’ Distinguished Leadership Award for her work in pharmacy practice leadership and academic pharmacy.
Transcript
What is the ASHP Board of Directors’ Distinguished Leadership Award, and what work have you done leading to you receiving this award at the 2023 ASHP Midyear Clinical Meeting & Exposition?
First, I want to thank ASHP Board of Directors for selecting me for the Distinguished Leadership Award. The award, to my understanding, is for individuals who have excellence in pharmacy practice leadership. I've done several things not only in pharmacy practice, but also in pharmacy practice leadership, including academic pharmacy, so I'm just honored.
ASHP is an organization that really means a lot to me. It's probably been there since the beginning with [my] residency training. I don't want to age myself here, but it's been decades that we have been friends and on this journey together. I also had the honor of being the founding chair, and now the past chair of the ASHP's new Section of Pharmacy Educators. And so that means a lot to me. It means a lot that ASHP has asked me to be involved in several things over the years.
So, that's a little bit about the award. I'm looking forward to receiving the award. My husband, John, is going to be there. And I'm just looking forward to seeing people again. I’m very excited about many things. Life is good.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More